Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RAPT Stock 12 Month Forecast
Average Price Target
$64.38
▲(118.39% Upside)
| Highest Price Target$72.00 | Average Price Target$64.38 | Lowest Price Target$56.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
$55→$57
Buy
93.35%
Upside
Reiterated
11/11/25
Barclays
$58→$56
Buy
89.96%
Upside
Reiterated
11/07/25
LifeSci Capital
$72→$68
Buy
130.66%
Upside
Reiterated
11/06/25
Promising Clinical and Financial Developments Drive Buy Rating for RAPT TherapeuticsThis morning, RAPT Therapeucs (Nasdaq: RAPT) reported Q3 2025 earnings and provided a corporate update. The largest highlight for the Company came in October, when topline data from the Phase 2 trial in CSU were reported from their Chinese partner Jeyou, with lead asset RPT904 – now officially named ozureprubart (our NOTE on the data). The readout was highly validang for the mAb, demonstrang numerically superior efficacy to Xolair (omalizumab) at up to a Q12W dosing interval, represenng a nice advance over the Q4W first- generaon standard-of-care (Xolair) in CSU. Addional details will be presented at an upcoming medical meeng. Following the posive results, RAPT raised $250M in gross proceeds from a stock offering, which should help operaons into mid-2028, including the iniaon of a Phase 3 program with ozureprubart in CSU.
H.C. Wainwright
$72
Buy
144.23%
Upside
Reiterated
11/06/25
Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth PlansValuation and Risks. Our Buy rating and $72 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2040 and assign a 12% discount rate and no terminal value. We currently assume value for RPT904 for the treatment of CSU with 45% POS and food allergy with 45% POS, and have not included other pipeline assets or indications in our valuation.
Clear Street
$60
Buy
103.53%
Upside
Reiterated
11/06/25
Wells Fargo
$48→$72
Buy
144.23%
Upside
Reiterated
11/03/25
Leerink Partners
$37→$60
Buy
103.53%
Upside
Reiterated
10/21/25
UBS
$8→$9
Hold
-69.47%
Downside
Reiterated
08/12/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
$55→$57
Buy
93.35%
Upside
Reiterated
11/11/25
Barclays
$58→$56
Buy
89.96%
Upside
Reiterated
11/07/25
LifeSci Capital
$72→$68
Buy
130.66%
Upside
Reiterated
11/06/25
Promising Clinical and Financial Developments Drive Buy Rating for RAPT TherapeuticsThis morning, RAPT Therapeucs (Nasdaq: RAPT) reported Q3 2025 earnings and provided a corporate update. The largest highlight for the Company came in October, when topline data from the Phase 2 trial in CSU were reported from their Chinese partner Jeyou, with lead asset RPT904 – now officially named ozureprubart (our NOTE on the data). The readout was highly validang for the mAb, demonstrang numerically superior efficacy to Xolair (omalizumab) at up to a Q12W dosing interval, represenng a nice advance over the Q4W first- generaon standard-of-care (Xolair) in CSU. Addional details will be presented at an upcoming medical meeng. Following the posive results, RAPT raised $250M in gross proceeds from a stock offering, which should help operaons into mid-2028, including the iniaon of a Phase 3 program with ozureprubart in CSU.
H.C. Wainwright
$72
Buy
144.23%
Upside
Reiterated
11/06/25
Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth PlansValuation and Risks. Our Buy rating and $72 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2040 and assign a 12% discount rate and no terminal value. We currently assume value for RPT904 for the treatment of CSU with 45% POS and food allergy with 45% POS, and have not included other pipeline assets or indications in our valuation.
Clear Street
$60
Buy
103.53%
Upside
Reiterated
11/06/25
Wells Fargo
$48→$72
Buy
144.23%
Upside
Reiterated
11/03/25
Leerink Partners
$37→$60
Buy
103.53%
Upside
Reiterated
10/21/25
UBS
$8→$9
Hold
-69.47%
Downside
Reiterated
08/12/25
Best Analysts Covering RAPT Therapeutics
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
+7.99%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +7.99% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
Average Return
+17.02%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +17.02% per trade.
1 Year
2 Years
xxx
Success Rate
8/17 ratings generated profit
Average Return
+44.33%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 47.06% of your transactions generating a profit, with an average return of +44.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RAPT Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
4
7
8
14
16
Buy
0
0
1
4
4
Hold
1
2
2
2
0
Sell
2
1
1
0
0
Strong Sell
0
0
0
0
0
total
7
10
12
20
20
Each month's total comprises the sum of three months' worth of ratings.
RAPT Financial Forecast
RAPT Stock Forecast FAQ
What is RAPT’s average 12-month price target, according to analysts?
Based on analyst ratings, RAPT Therapeutics’s 12-month average price target is 64.38.
What is RAPT’s upside potential, based on the analysts’ average price target?
RAPT Therapeutics has 118.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RAPT a Buy, Sell or Hold?
RAPT Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is RAPT Therapeutics’s price target?
The average price target for RAPT Therapeutics is 64.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $72.00 ,the lowest forecast is $56.00. The average price target represents 118.39% Increase from the current price of $29.48.
The highest analyst price target is $72.00 ,the lowest forecast is $56.00. The average price target represents 118.39% Increase from the current price of $29.48.
What do analysts say about RAPT Therapeutics?
RAPT Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of RAPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.